- Report
- July 2024
- 143 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- March 2025
- 193 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- April 2024
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- April 2024
- 140 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- June 2024
- 140 Pages
Europe
From €3678EUR$3,869USD£3,090GBP
- Report
- June 2024
- 140 Pages
Asia Pacific
From €3678EUR$3,869USD£3,090GBP
- Report
- June 2024
- 120 Pages
North America
From €3678EUR$3,869USD£3,090GBP
- Report
- June 2024
- 140 Pages
Latin America
From €3678EUR$3,869USD£3,090GBP
- Report
- September 2023
- 129 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- July 2023
- 107 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- October 2023
- 146 Pages
Global
From €3353EUR$3,528USD£2,817GBP
€3945EUR$4,150USD£3,314GBP
In Vitro Colorectal Cancer Screening Tests are a type of In Vitro Diagnostics (IVD) used to detect colorectal cancer in individuals. These tests are typically performed on a sample of stool, which is then analyzed for the presence of certain biomarkers associated with colorectal cancer. The most common type of test is the fecal immunochemical test (FIT), which detects the presence of human hemoglobin in the stool. Other tests include the fecal occult blood test (FOBT), which detects the presence of blood in the stool, and the stool DNA test, which detects the presence of mutated DNA in the stool.
The In Vitro Colorectal Cancer Screening Tests market is a rapidly growing segment of the IVD market, driven by increasing awareness of the importance of early detection of colorectal cancer. The market is expected to continue to grow in the coming years, as more countries adopt screening programs and as new technologies are developed.
Some of the major companies in the In Vitro Colorectal Cancer Screening Tests market include Roche Diagnostics, Abbott Laboratories, Becton Dickinson, Siemens Healthineers, and Quest Diagnostics. Show Less Read more